Immuneering Corp Stock Price, News & Analysis

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced the pricing of a significant $175 million public offering of Class A common stock at $9.23 per share, consisting of 18,959,914 shares. The company has also granted underwriters a 30-day option to purchase up to 2,843,987 additional shares.

Concurrent with the public offering, Sanofi has agreed to make a $25 million private placement investment, purchasing 2,708,559 shares at the same price per share. Both transactions are expected to close around September 26, 2025. The proceeds will be used to advance Immuneering's preclinical and clinical development programs and for general corporate purposes.

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced a proposed underwritten public offering of its Class A common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to 15% additional Class A common stock shares.

Simultaneously, Sanofi has agreed to invest $25.0 million in a concurrent private placement, purchasing either Class A or non-voting Class B common stock at the same price as the public offering. Leerink Partners and Oppenheimer & Co. Inc. are serving as joint bookrunners for the offering and placement agents for the private placement.

The proceeds will be used to advance Immuneering's preclinical and clinical product development and for general corporate purposes. The offering is subject to market conditions, and the private placement is contingent upon the offering's closing.

Immuneering (Nasdaq: IMRX) reported exceptional clinical trial results for atebimetinib combined with mGnP in first-line pancreatic cancer treatment. The Phase 2a trial (N=34) demonstrated remarkable 86% overall survival (OS) at 9 months, significantly outperforming the standard of care benchmark of ~47%. The study also showed 53% progression-free survival (PFS) at 9 months, compared to the standard ~29%.

The drug maintained a favorable tolerability profile, with only two Grade 3 adverse events occurring in more than 10% of patients. Atebimetinib, a Deep Cyclic Inhibitor targeting MEK, represents a novel approach in targeted therapy by pulsing faster than tumors can adapt. The company expects regulatory feedback on pivotal trial plans in Q4 2025 and aims to initiate a Phase 3 trial by year-end.

Immuneering (Nasdaq: IMRX) has appointed Dr. Thomas J. Schall as Chairman of the Board of Directors. Dr. Schall, who joined the board in March 2024, brings over 30 years of leadership in drug discovery and development, most notably as founder and CEO of ChemoCentryx, which was acquired by Amgen for $4 billion in 2022.

The appointment comes as Immuneering prepares to announce updated data from its phase 2a study of atebimetinib + mGnP in first-line pancreatic cancer patients on September 25, 2025, with additional presentation at the PanCAN Annual Scientific Summit. The strategic timing of Dr. Schall's appointment signals the company's preparation for pivotal studies, registration filings, and commercialization plans.

Immuneering (NASDAQ:IMRX) announced plans to release updated overall survival data from its Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients on September 25, 2025. The trial data, with 9 months median follow-up, follows previously reported exceptional 94% overall survival at 6 months, significantly outperforming the standard of care's 67% survival rate.

The company will present the data through an investor call and webcast, followed by a presentation at the PanCAN Scientific Summit on September 28. Additionally, Immuneering will present preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit on September 17.

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has successfully closed a $25 million private placement with institutional and accredited investors. The transaction included the sale of 6,329,113 unregistered shares of Class A common stock at $3.95 per share, along with warrants to purchase 2,848,096 additional shares at $5.50 per share.

The offering also included pre-funded warrants at $3.949 per share. The purchase warrants have a five-year exercise period following registration. Leerink Partners served as financial advisor for the placement, which was conducted as a private transaction under Securities Act regulations.

Immuneering (Nasdaq: IMRX) has entered into a clinical supply agreement with Eli Lilly to evaluate its lead product candidate atebimetinib in combination with Lilly's olomorasib in a planned Phase 2 trial. The study will focus on patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy.

This marks Immuneering's second major collaboration in 2025, following a February agreement with Regeneron to evaluate atebimetinib with Libtayo®. Preclinical studies of the atebimetinib-olomorasib combination have shown promising results, including enhanced tumor regression and delayed resistance. Immuneering will retain global development and commercialization rights to atebimetinib.

Immuneering (Nasdaq: IMRX) has secured a $25 million private placement from institutional and accredited investors. The company is offering 6,329,113 shares at $3.95 per share, a 15% premium to the previous closing price, along with warrants to purchase 2,848,096 additional shares at $5.50 per share.

The financing was driven by strong investor interest following impressive clinical results, including a 94% overall survival rate at 6 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP, significantly outperforming the standard of care's 67% survival rate. The funding will support the development of Deep Cyclic Inhibitors, including atebimetinib, a MEK inhibitor targeting the MAPK pathway.

Immuneering (NASDAQ:IMRX) reported Q2 2025 financial results and significant clinical progress for its lead drug atebimetinib. The company highlighted exceptional 94% overall survival at 6 months in first-line pancreatic cancer patients (N=34) treated with atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP), compared to 67% with standard care.

Key developments include a newly granted U.S. composition of matter patent extending exclusivity into 2042, and a notable case of a third-line pancreatic cancer patient maintaining partial response for over 18 months on atebimetinib monotherapy. The company reported Q2 2025 net loss of $14.4 million ($0.40 per share) and cash position of $26.4 million, with runway into 2026.

Immuneering plans to share updated survival data in Q3 2025 and has submitted an End of Phase 2 meeting request to FDA, with pivotal trial initiation expected in 2026.